Provexis plc (PXS) - Total Assets
Based on the latest financial reports, Provexis plc (PXS) holds total assets worth GBX841.84K GBX (≈ $102.43 USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See shareholders equity of Provexis plc for net asset value and shareholders' equity analysis.
Provexis plc - Total Assets Trend (2004–2025)
This chart illustrates how Provexis plc's total assets have evolved over time, based on quarterly financial data.
Provexis plc - Asset Composition Analysis
Current Asset Composition (March 2025)
Provexis plc's total assets of GBX841.84K consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (GBX) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 70.0% |
| Accounts Receivable | GBX79.01K | 7.8% |
| Inventory | GBX202.35K | 20.0% |
| Property, Plant & Equipment | GBX0.00 | 0.0% |
| Intangible Assets | GBX0.00 | 0.0% |
| Goodwill | GBX0.00 | 0.0% |
Asset Composition Trend (2004–2025)
This chart illustrates how Provexis plc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Provexis plc stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Provexis plc's current assets represent 100.0% of total assets in 2025, an increase from 94.7% in 2004.
- Cash Position: Cash and equivalents constituted 70.0% of total assets in 2025, up from 57.9% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2004.
- Asset Diversification: The largest asset category is inventory at 20.0% of total assets.
Provexis plc Competitors by Total Assets
Key competitors of Provexis plc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Yabao Pharmaceutical Group Co Ltd
SHG:600351
|
China | CN¥3.34 Billion |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
Sandoz Group AG
SW:SDZ
|
Switzerland | CHF21.61 Billion |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr67.43 Billion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.22 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
Provexis plc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.65 | 1.75 | 2.32 |
| Quick Ratio | 3.45 | 1.42 | 1.84 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | GBX610.89K | GBX351.39K | GBX223.29K |
Provexis plc - Advanced Valuation Insights
This section examines the relationship between Provexis plc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 19.98 |
| Latest Market Cap to Assets Ratio | 0.29 |
| Asset Growth Rate (YoY) | 103.2% |
| Total Assets | GBX1.01 Million |
| Market Capitalization | $291.14K USD |
Valuation Analysis
Below Book Valuation: The market values Provexis plc's assets below their book value (0.29x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Provexis plc's assets grew by 103.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Provexis plc (2004–2025)
The table below shows the annual total assets of Provexis plc from 2004 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | GBX1.01 Million ≈ $123.13 |
+103.20% |
| 2024-03-31 | GBX498.04K ≈ $60.60 |
-41.13% |
| 2023-03-31 | GBX845.99K ≈ $102.93 |
-24.93% |
| 2022-03-31 | GBX1.13 Million ≈ $137.12 |
-12.83% |
| 2021-03-31 | GBX1.29 Million ≈ $157.30 |
+175.81% |
| 2020-03-31 | GBX468.76K ≈ $57.03 |
+1.46% |
| 2019-03-31 | GBX462.03K ≈ $56.22 |
+10.36% |
| 2018-03-31 | GBX418.64K ≈ $50.94 |
+164.63% |
| 2017-03-31 | GBX158.20K ≈ $19.25 |
-38.34% |
| 2016-03-31 | GBX256.58K ≈ $31.22 |
-28.72% |
| 2015-03-31 | GBX359.98K ≈ $43.80 |
-44.04% |
| 2014-03-31 | GBX643.29K ≈ $78.27 |
-93.80% |
| 2013-03-31 | GBX10.37 Million ≈ $1.26K |
-22.69% |
| 2012-03-31 | GBX13.41 Million ≈ $1.63K |
+11.37% |
| 2011-03-31 | GBX12.04 Million ≈ $1.47K |
+6.06% |
| 2010-03-31 | GBX11.36 Million ≈ $1.38K |
+96.96% |
| 2009-03-31 | GBX5.77 Million ≈ $701.56 |
-27.44% |
| 2008-03-31 | GBX7.95 Million ≈ $966.80 |
+6.69% |
| 2007-03-31 | GBX7.45 Million ≈ $906.21 |
-22.87% |
| 2006-03-31 | GBX9.66 Million ≈ $1.17K |
+564.62% |
| 2005-03-31 | GBX1.45 Million ≈ $176.79 |
+349.85% |
| 2004-03-31 | GBX323.00K ≈ $39.30 |
-- |
About Provexis plc
Provexis plc, together with its subsidiaries, develops, licenses, and sells functional foods, medical foods, and dietary supplements worldwide. The company offers syrup and powder versions of Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke used in various foods, beverages, and di… Read more